Pain-preventing NSAID welcomed by patients and clinicians
A new 0.075% formulation of bromfenac ophthalmic solution (BromSite, Sun Pharma) could provide relief from pain and inflammation associated with cataract surgery.
By Laird Harrison; Reviewed by Sheri Rowen, MD
A new 0.075% formulation of bromfenac ophthalmic solution (BromSite, Sun Pharma) could provide relief from pain and inflammation associated with cataract surgery, according to Sheri Rowen, MD, of Nvision Eye Centers, Newport Beach, CA.
Last April, the FDA approved the nonsteroidal anti-inflammatory drug (NSAID) to prevent pain and treat inflammation associated with cataract surgery, Sun Pharma announced.
Recent:
“According to the study data, it has good aqueous concentrations of the molecule after 1 drop,” Dr. Rowen said. “So that is an encouraging sign.”
Sun Pharma’s U.S. subsidiary, Sun Ophthalmics, began marketing BromSite in the United States last fall.
The agent delivers bromfenac in a synthetic polymer of crosslinked polyacrylic acid developed as DuraSite by InSite Vision. DuraSite is also the vehicle for Bausch + Lomb’s besifloxacin ophthalmic suspension (Besivance) and Akorn’s azithromycin ophthalmic solution (AzaSite).
Related:
DuraSite is mucoadhesive and “can be used to improve solubility, absorption, bioavailability and residence time as compared to conventional topical therapies,” according to Sun Pharma. Sun Pharma of Mumbai, India, purchased InSite Vision of Alameda, CA, in November 2015.
The active ingredient is suspended in the DuraSite and is released in small doses each time the patient blinks, Dr. Rowen explained.
More:
The label calls for twice-daily dosing, morning and evening, beginning 1 day before surgery and ending 14 days after.
Bromfenac, the active ingredient of BromSite, inhibits cyclooxygenase (cox) 1 and 2, enzymes responsible for forming prostaglandins.
Internal server error